Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines

Szu Chun Hung, Ko Lin Kuo, Der Cherng Tarng, Chih Cheng Hsu, Mai Szu Wu, Tung Po Huang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit

Original languageEnglish
Pages (from-to)735-739
Number of pages5
JournalNephrology
Volume19
Issue number12
DOIs
Publication statusPublished - Dec 1 2014
Externally publishedYes

Fingerprint

Hematinics
Taiwan
Chronic Renal Insufficiency
Practice Guidelines
Anemia
National Health Programs
Hematocrit
Creatinine
Serum

Keywords

  • anaemia
  • chronic kidney disease
  • erythropoietin
  • iron
  • Taiwan

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Hung, S. C., Kuo, K. L., Tarng, D. C., Hsu, C. C., Wu, M. S., & Huang, T. P. (2014). Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology, 19(12), 735-739. https://doi.org/10.1111/nep.12332

Anaemia management in patients with chronic kidney disease : Taiwan practice guidelines. / Hung, Szu Chun; Kuo, Ko Lin; Tarng, Der Cherng; Hsu, Chih Cheng; Wu, Mai Szu; Huang, Tung Po.

In: Nephrology, Vol. 19, No. 12, 01.12.2014, p. 735-739.

Research output: Contribution to journalArticle

Hung, SC, Kuo, KL, Tarng, DC, Hsu, CC, Wu, MS & Huang, TP 2014, 'Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines', Nephrology, vol. 19, no. 12, pp. 735-739. https://doi.org/10.1111/nep.12332
Hung, Szu Chun ; Kuo, Ko Lin ; Tarng, Der Cherng ; Hsu, Chih Cheng ; Wu, Mai Szu ; Huang, Tung Po. / Anaemia management in patients with chronic kidney disease : Taiwan practice guidelines. In: Nephrology. 2014 ; Vol. 19, No. 12. pp. 735-739.
@article{6d60bffdacd54045bcbf70ddc6d6439a,
title = "Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines",
abstract = "The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit",
keywords = "anaemia, chronic kidney disease, erythropoietin, iron, Taiwan",
author = "Hung, {Szu Chun} and Kuo, {Ko Lin} and Tarng, {Der Cherng} and Hsu, {Chih Cheng} and Wu, {Mai Szu} and Huang, {Tung Po}",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/nep.12332",
language = "English",
volume = "19",
pages = "735--739",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Anaemia management in patients with chronic kidney disease

T2 - Taiwan practice guidelines

AU - Hung, Szu Chun

AU - Kuo, Ko Lin

AU - Tarng, Der Cherng

AU - Hsu, Chih Cheng

AU - Wu, Mai Szu

AU - Huang, Tung Po

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit

AB - The introduction of erythropoiesis-stimulating agents (ESAs) markedly improved the lives of many anaemic patients with chronic kidney disease (CKD). In Taiwan, the strategy of management of anaemia in patients with CKD was different from many other parts of the world. In 1996, the National Health Insurance Administration of Taiwan applied a more restrictive reimbursement criteria for ESA use in patients with CKD. ESA is to be initiated when non-dialysis CKD patients have a serum creatinine >6 mg/dL and a hematocrit

KW - anaemia

KW - chronic kidney disease

KW - erythropoietin

KW - iron

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=84936747571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936747571&partnerID=8YFLogxK

U2 - 10.1111/nep.12332

DO - 10.1111/nep.12332

M3 - Article

C2 - 25156587

AN - SCOPUS:84936747571

VL - 19

SP - 735

EP - 739

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 12

ER -